Bli medlem
Bli medlem

Du är här

2014-08-06

Elekta: For fourth year in a row, Elekta's Leksell Gamma Knife Perfexion earns top rank in 2014's Best in KLAS for Radiation Therapy

ATLANTA, August 7 - Elekta's Leksell Gamma Knife® Perfexion™
(http://www.elekta.com/perfexion) radiosurgery system took the first
place ranking for the fourth consecutive year in KLAS research firm's
recently released 2014 Best in KLAS Awards: Medical & Infrastructure
report*. In addition, Elekta's Agility™ 160-leaf multi-leaf
collimator (MLC) and Elekta Infinity™ radiation treatment system
earned second and third place.

In the report, Perfexion scored 94.5 out of 100 on the system's
functionality and upgrade capacity. Perfexion also scored between
90.5 and 93.5 on four other performance categories, including service
and support, and implementation and training.

"Virtually all of our Leksell Gamma Knife sites also have access to
linacs for radiosurgery," says Jay Hoey, Executive Vice President,
Elekta North America. "We feel the KLAS study highlights the fact
that, when it comes to brain radiosurgery, the clear preference is
for Gamma Knife. Gamma Knife centers appreciate the system's high
efficiency, uptime and unparalleled clinical capability. We are
honored by their recognition."

Further documenting the superior dosimetric performance of Perfexion,
a recent multicenter study1 showed that the system offers
dramatically lower radiation dose to normal brain - in the treatment
of multiple metastases - than other systems, such as Varian's
TrueBeam™ flattening filter-free linear accelerator with a 2.5 mm
MLC. Patients with multiple metastases, the report said, stand to
receive as much as a 74 percent lower radiation dose to normal brain
tissues if the lesions are treated with Perfexion versus contemporary
linear accelerator-based stereotactic (SRS) systems.

KLAS surveys include opinions of thousands of health care
professionals

The KLAS awards are based on data from customer surveys of hospital
and clinic executives, administrators, physicians, nurses and other
directors and managers interacting with health care equipment and
infrastructure solutions.

According to KLAS, Best in KLAS designations go to solutions that have
excelled in their respective market segments, that show the vendor's
leadership in working with customers to resolve issues and match
expectations to reality, and that have the broadest operational and
clinical impact to health care organizations.

The Best in KLAS designation recognizes vendors for their outstanding
efforts to help healthcare professionals deliver better patient care.
This award is reserved for those that lead the imaging equipment
segments with the broadest operational and clinical impact on
healthcare organizations.

"This is a tremendous achievement because each of the top performers
earned this recognition through the voice of their provider
customers," says Matt Terry, vice president of medical equipment and
imaging research for KLAS. "Given that vendors must concern
themselves with the complexities of a dynamic health care market and
operational challenges, it is remarkable to see so many undeviating
from their focus on helping providers succeed."

*2014 Best in KLAS Award: Medical Equipment & Infrastructure, July
2014. © 2014 KLAS Enterprises, LLC. All rights reserved.
www.KLASresearch.com http://www.klasresearch.com/klasreports/

1. Ma L, Nichol A, Hossain S, et al. (2014) Variable dose interplay
effects across radiosurgical apparatus in treating multiple brain
metastases. Int J CARS. Published online: 20 April 2014.
doi:10.1007/s11548-014-1001-4

# # #

For further information, please contact:
Gert van Santen, Group Vice President Corporate Communications, Elekta
AB

Tel: +31 653 561 242, e-mail: gert.vansanten@elekta.com
Time zone: CET: Central European Time
Raven Canzeri, Global Public Relations Manager, Elekta
Tel: +1 770-670-2524, e-mail: raven.canzeri@elekta.com
Time zone: ET: Eastern Time

About Elekta
Elekta is a human care company pioneering significant innovations and
clinical solutions for treating cancer and brain disorders. The
company develops sophisticated, state-of-the-art tools and treatment
planning systems for radiation therapy, radiosurgery and
brachytherapy, as well as workflow enhancing software systems across
the spectrum of cancer care. Stretching the boundaries of science and
technology, providing intelligent and resource-efficient solutions
that offer confidence to both health care providers and patients,
Elekta aims to improve, prolong and even save patient lives.

Today, Elekta solutions in oncology and neurosurgery are used in over
6,000 hospitals worldwide. Elekta employs around 3,800 employees
globally. The corporate headquarters is located in Stockholm, Sweden,
and the company is listed on the Nordic Exchange under the ticker
STO:EKTAB. Website: www.elekta.com.

-----------------------------------------------------------
http://news.cision.com/elekta/r/for-fourth-year-in-a-row--elekta-s-lekse...
http://mb.cision.com/Main/35/9624835/272378.pdf

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.